目的：评价外周血白介素–35水平与肿瘤危险的相关性。方法：计算机检索PubMed、MEDLINE、EMBASE、CNKI和万方等数据库，检索2015年1月15日以前公开发表的文献。采用RevMan5.2.2分析软件对其进行分析和评价。结果：通过检索，最终纳入5篇研究。Meta分析结果显示外周血白介素–35浓度在癌症患者和正常组之间无明显差别(MD =41.91；95% CI，−6.33~90.15；P=0.09)。亚组分析也表明IL-35在白血病或其他癌症与正常对照组之间并无显著差异(MD =23.73；95% CI，−15.63~63.09；P=0.24)；(MD =60.00；95% CI，−57.86~177.87；P=0.32)。性别研究分析表明，男性癌症患者中的外周血IL-35浓度与女性患者之间并无显著差异(MD =−3.25，95% CI，−8.39~1.88；P=0.21)。外周血IL-35在癌症淋巴结转移和无淋巴结转移病人中存在显著差异(MD =−23.18，95% CI，−37.93~−8.43, P=0.002)。结论：外周血IL-35浓度在癌症病人中并无显著相关性，但是可以作为癌症淋巴结转移有无的一个预测指标。
Meta-analysis of association of circulation interleukin-35 with cancer
Objective: To review systematically the association of circulation interleukin 35 (IL-35) with cancer risk. Methods: The databases of PubMed, MEDLINE, EMBASE, China National Knowledge Infrastructure (CNKI) and WangFang up to Jan 15, 2015 were searched for relevant articles. Meta-analysis was conducted using RevMan 5.2.2 software. Results: Total five studies were finally included into this meta-analysis. The results of meta-analysis shown that no association of circulation IL-35 level between cancer patients and controls (MD =41.91; 95% CI, −6.33~90.15; P=0.09). Subgroups analysis also shown that there were no significantly differences on IL-35 level between leukemia or other cancers and controls (MD =23.73, 95% CI, −15.63~63.09; P=0.24; MD =60.00, 95% CI, −57.86~177.87; P=0.32; respectively). Moreover, no associated to IL-35 between male and female patients (MD =−3.25, 95% CI, −8.39~1.88, P=0.21). However, there was a significantly difference on association between lymph node metastasis and no-lymph node metastasis (MD =−23.18, 95% CI, −37.93~−8.43, P=0.002). Conclusion: No association between cancer patients and controls, but it can be as a predictor for lymph node metastasis patients.